SCHEMBL1831454

SCHEMBL1831454

ClC(Cl)(Cl)c1nc(-c2ccc3ccccc3n2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.45
▸ RAB9A P51151 5/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ TP53 P04637 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ PKM P14618 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ HCRTR1 O43613 1/20 0.45
▸ SMO Q99835 11/20 0.43
▸ ERG P11308 1/20 0.43
▸ AR P10275 2/20 0.40
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC8 Q9BY41 2/20 0.40
▸ HDAC6 Q9UBN7 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4954112 0.74 HTT (0.59) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3634573 0.73 NR1H4 (0.57) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL24184547 0.71 RAB9A (0.61) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL9396180 0.71 RAB9A (0.61) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2159096 0.70 NPC1 (0.51) NPC1RAB9AALDH1A1HSD17B10TP53
SCHEMBL9782308 0.69 STAT3 (0.40) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4552305 0.69 RAB9A (0.68) NPC1RAB9AALDH1A1HSD17B10SMO
SCHEMBL170196 0.69 RAB9A (0.64) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL29374931 0.69 RAB9A (0.64) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL31665931 0.68 NCF1 (0.46) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183974-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) 2011-07-28 — — US disclosed
EP-2318400-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2011-05-11 — — EP disclosed
WO-2010013037-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2010-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183974-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS SHH, SMO, GLI1 NPC1 2688/4885RAB9A 2234/4885MEN1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback